Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating subcutaneously administered guselkumab for chronic plaque psoriasis shows active/not recruiting with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-28